<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) June 1, 2000
------------
BOSTON LIFE SCIENCES, INC.
--------------------------
(Exact name of registrant as specified in its charter)
<TABLE>
<CAPTION>
<S> <C> <C>
Delaware 0-6533 87-0277826
------------------------------------------ ----------- ------------------------------------
(State or other jurisdiction of (Commission (I.R.S. Employer Identification No.)
incorporation or organization) File No.)
137 Newbury Street
8th Floor
Boston, Massachusetts 02116
------------------------------------------ ------------------------------------
(Address of principal executive offices) Zip Code
</TABLE>
Registrant's telephone number, including area code (617) 425-0200
-----------------
<PAGE>
Item 5. Other Events.
-------------
On June 1, 2000 Boston Life Sciences, Inc. entered into and closed an agreement
to sell $10 million of the Company's common stock to an institutional investment
fund. Under the terms of the financing, the Company issued 1,405,956 shares of
common stock to the Pictet Global Sector Fund - Biotech. The effective purchase
price of $7.113 per share was based on the weighted average closing price for
the ten trading days ending May 26, 2000.
The Company also issued two classes of warrants: the first, or "Class C"
warrants, are exercisable to purchase 300,000 shares of common stock at an
exercise price of $8.00 per share. The second, or "Class D" warrants, are
exercisable to purchase 200,000 shares of common stock at an exercise price of
$10.00 per share.
The Company is obligated to file a registration statement covering resales of
common stock issued at closing and issuable upon exercise of the warrants within
30 days of closing.
Copies of the material agreements related to the transaction as well as the
press release announcing the transaction are filed as exhibits to this Form 8-K
and incorporated herein by reference.
<PAGE>
ITEM 7. Financial Statements, Pro Forma Financial Information and Exhibits.
------------------------------------------------------------------
(C) Exhibits:
--------
10.1 Purchase Agreement among the Company and the purchasers listed therein
dated as of June 1, 2000.
10.2 Schedule 4.3 (to the Purchase Agreement).
10.3 Schedule 4.16 (to the Purchase Agreement).
10.4 Registration Rights Agreement among the Company and the purchasers
dated as of June 1, 2000.
10.5 Form of Warrant dated as of June 1, 2000.
99.1 Press Release issued June 1, 2000 announcing the transaction.
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BOSTON LIFE SCIENCES INC.
Date: June 9, 2000 By: /s/ Joseph Hernon
----------------------------
Name: Joseph Hernon
Title: Chief Financial Officer and
Secretary
<PAGE>
EXHIBIT INDEX
The following designated exhibits are filed herewith:
Exhibits
--------
10.1 Purchase Agreement among the Company and the purchasers listed therein
dated as of June 1, 2000.
10.2 Schedule 4.3 (to the Purchase Agreement).
10.3 Schedule 4.16 (to the Purchase Agreement).
10.4 Registration Rights Agreement among the Company and the purchasers
dated as of June 1, 2000.
10.5 Form of Warrant dated as of June 1, 2000.
99.1 Press Release issued June 1, 2000 announcing the transaction.
